Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

The solution will use Owkin's data network and artificial intelligence to pre-screen for gBRCA mutations in breast cancer directly from digital pathology slides.

A mesothelioma prognostic model from medical machine learning firm Owkin has been showcased in the journal Nature, and is being used to help further drug research into the often fatal disease.

The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.

France’s Servier has become the latest pharma group to tap into an artificial intelligence platform for drug discovery, development, and diagnostics developed by Franco-US biotech Owkin.

Change is coming through AI, with the potential to better decipher human biology and disease. All tech companies start from ...

EOT.AI, a leader in AI-powered solutions for industrial enterprises, has announced the upcoming release of its innovative ...

Owkin’s solution is to bring academic and pharmaceutical industry researchers together in a federated research environment. Here, the company’s proprietary infrastructure and artificial ...

Owkin’s research has helped it develop an AI-powered approach that identifies the best covariates and how to adjust for them. As a result, Owkin believes it can help the pharmaceutical industry ...

En’owkin, practiced as a rules-to-order technique, solicits voluntary deep collaboration. As such, En’owkin is engaged in by the community as a customary procedure in order to insure that the ...

SAN DIEGO — The novel antibody-drug conjugate tusamitamab ravtansine (tusa rav, Sanofi) did not demonstrate greater efficacy than docetaxel in treating advanced nonsquamous non–small cell lung ...